Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators

Endocrinology

Volumn 154, Issue 3, 2013, Pages 1105-1116

  Leach, Katie ^a   Wen, Adriel ^a   Cook, Anna E ^a   Sexton, Patrick M ^a   Conigrave, Arthur D ^b   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM SENSING RECEPTOR; CINACALCET; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL SURFACE; FUNCTIONAL DISEASE; GENE EXPRESSION; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ALLOSTERIC REGULATION; AMINO ACID SUBSTITUTION; CALCIUM SIGNALING; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEK293 CELLS; HUMANS; MUTANT PROTEINS; MUTATION; NAPHTHALENES; RECEPTORS, CALCIUM-SENSING; RECOMBINANT PROTEINS;

EID: 84874595491     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1887     Document Type: Article

References (29)

1. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516-1525.
2. Reh CM, Hendy GN, Cole DE, Jeandron DD. Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CaSR) R185Q mutation: Clinical benefit from cinacalcet. J Clin Endocrinol Metab. 2011;96:E707-E712.
3. Timmers HJ, Karperien M, Hamdy NA, de Boer H, Hermus AR. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calciumsensing receptor. J Intern Med. 2006;260:177-182.
4. Wilhelm-Bals A, Parvex P, Magdelaine C, Girardin E. Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism. Pediatrics. 2012;129:e812-e816.
5. Cavanaugh A,McKennaJ, Stepanchick A, Breitwieser GE. Calciumsensing receptor biosynthesis includes a cotranslational conformational checkpoint and endoplasmic reticulum retention. J Biol Chem. 2010;285:19854-19864.
6. Huang Y, Breitwieser GE. Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis. J Biol Chem. 2007;282:9517-9525.
7. White E, McKenna J, Cavanaugh A, Breitwieser GE. Pharmacochaperone- mediated rescue of calcium-sensing receptor loss-offunction mutants. Mol Endocrinol. 2009;23:1115-1123.
8. Lu JY, Yang Y, Gnacadja G, Christopoulos A, Reagan JD. Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl) ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor. J Pharmacol Exp Ther. 2009;331:775-786.
9. Ray K, Northup J. Evidence for distinct cation and calcimimetic compound (NPS 568) recognition domains in the transmembrane regions of the human Ca2+ receptor. J Biol Chem. 2002;277: 18908-18913.
10. BuL, MichinoM,WolfRM,BrooksCL3rd. Improved model building and assessment of the calcium-sensing receptor transmembrane domain. Proteins. 2008;71:215-226.
11. Hu J, Jiang J, Costanzi S, et al. A missense mutation in the seventransmembrane domain of the human Ca2+ receptor converts a negative allosteric modulator into a positive allosteric modulator. J Biol Chem. 2006;281:21558-21565.
12. Miedlich SU, Gama L, Seuwen K, Wolf RM, Breitwieser GE. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J Biol Chem. 2004;279:7254-7263.
13. Petrel C, Kessler A, Dauban P, Dodd RH, Rognan D, Ruat M. Positive and negative allosteric modulators of theCa2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem. 2004;279:18990-18997.
14. Petrel C, Kessler A, Maslah F, et al. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca2+-sensing receptor. J Biol Chem. 2003;278: 49487-49494.
15. Leach K,WenA, Davey AE, Sexton P, Conigrave AD, Christopoulos A. Identification of molecular phenotypes and biased signaling induced by naturally occurring mutations of the human calcium sensing receptor. Endocrinology. 2012;153:4306-4316.
16. Nawaratne V, Leach K, Suratman N, et al. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol Pharmacol. 2008;74: 1119-1131.
17. Davey AE, Leach K, Valant C, Conigrave AD, Sexton PM, Christopoulos A. Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. Endocrinology. 2012;153:1232-1241.
18. Bernier V, Lagace M, Lonergan M, Arthus MF, Bichet DG, Bouvier M. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol. 2004;18:2074-2084.
19. Morello JP, Salahpour A, Laperriere A, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest. 2000;105:887-895.
20. Wuller S, Wiesner B, Loffler A, et al. Pharmacochaperones posttranslationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. J Biol Chem. 2004;279:47254-47263.
21. Robben JH, Sze M, Knoers NV, Deen PM. Functional rescue of vasopressin V2 receptor mutants inMDCKcells by pharmacochaperones: Relevance to therapy of nephrogenic diabetes insipidus.AmJ Physiol Renal Physiol. 2007;292:F253-F260.
22. Noorwez SM, Kuksa V, Imanishi Y, et al. Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. J Biol Chem. 2003;278:14442-14450.
23. Janovick JA, Maya-Nunez G, Conn PM. Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: Misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab. 2002;87:3255-3262.
24. Janovick JA, Goulet M, Bush E, Greer J, Wettlaufer DG, Conn PM. Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. J Pharmacol Exp Ther. 2003;305:608-614.
25. Chonchol M, Locatelli F, Abboud HE, et al. A randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants withCKDnot receiving dialysis.AmJ Kidney Dis. 2009;53:197-207.
26. Grant MP, Stepanchick A, Cavanaugh A, Breitwieser GE. Agonistdriven maturation and plasma membrane insertion of calcium-sensing receptors dynamically control signal amplitude. Sci Signal. 2011; 4:ra78.
27. Grant MP, Stepanchick A, Breitwieser GE. Calcium signaling regulates trafficking of familial hypocalciuric hypercalcemia (FHH) mutants of the calcium sensing receptor. Mol Endocrinol. 2012;26: 2081-2091.
28. Thomsen AR, Hvidtfeldt M, Brauner-Osborne H. Biased agonism of the calcium-sensing receptor. Cell Calcium. 2012;51:107-116.
29. Christopoulos A. Assessing the distribution of parameters in models of ligand-receptor interaction: To log or not to log. Trends Pharmacol Sci. 1998;19:351-357.